Literature DB >> 17620589

Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia.

Jill S Melicher Larson1, Lance K Bergstrom, J Douglas Cameron, Lori A Erickson, Terrence E Grimm.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17620589     DOI： 10.1001/archopht.125.7.985

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


× No keyword cloud information.
  6 in total

1.  Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas.

Authors:  Boaz Karmazyn; Mervyn D Cohen; Samuel Gregory Jennings; Kent A Robertson
Journal:  Pediatr Radiol       Date:  2012-06-22

Review 2.  Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.

Authors:  Dakota Gustafson; Jason E Fish; Jeffrey H Lipton; Nazanin Aghel
Journal:  Curr Hematol Malig Rep       Date:  2020-02       Impact factor: 3.952

3.  Bilateral papilledema on sunitinib therapy for advanced renal cell carcinoma.

Authors:  Jaclyn Yoong; Geoffrey Chong; K Hamilton
Journal:  Med Oncol       Date:  2010-11-04       Impact factor: 3.064

Review 4.  Ocular Toxicity of Tyrosine Kinase Inhibitors.

Authors:  Mary Elizabeth Davis
Journal:  Oncol Nurs Forum       Date:  2016-03       Impact factor: 2.172

5.  Periorbital edema secondary to imatinib mesylate.

Authors:  Collin M McClelland; George J Harocopos; Philip L Custer
Journal:  Clin Ophthalmol       Date:  2010-05-14

6.  [Fundus leucaemicus as first manifestation of chronic myeloid leukemia. Diagnosis and monitoring with OCT under treatment with imatinib and interferon-alpha].

Authors:  E Chankiewitz; G A Scholz; B M Spriewald; A Mackensen; A Bergua
Journal:  Ophthalmologe       Date:  2010-04       Impact factor: 1.059
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.